Trials / Recruiting
RecruitingNCT06088979
A Study to Investigate Efficacy and Safety of TOUR006 in Participants 18 to 80 Years of Age With Thyroid Eye Disease
A Multicenter Phase 2b Randomized, Double-Masked, Placebo-Controlled Dose-Ranging Study of TOUR006 in Participants With Thyroid Eye Disease
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 81 (estimated)
- Sponsor
- Tourmaline Bio, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Phase 2b trial of TOUR006 in Thyroid Eye Disease (TED) to evaluate 20mg and 50mg doses against placebo given by a subcutaneous injection every eight weeks to TED patients who are in the active inflammatory phase of disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TOUR006 - 20 MG | TOUR006 20 MG |
| OTHER | Placebo | Placebo |
| DRUG | TOUR006 - 50 MG | TOUR006 - 50 MG |
Timeline
- Start date
- 2024-02-19
- Primary completion
- 2026-09-01
- Completion
- 2027-09-01
- First posted
- 2023-10-18
- Last updated
- 2026-01-30
Locations
56 sites across 12 countries: United States, Brazil, Canada, France, Italy, Jordan, Latvia, New Zealand, Puerto Rico, Slovakia, South Korea, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06088979. Inclusion in this directory is not an endorsement.